Management of Persons with Hemophilia A with Inhibitors After Emicizumab Approval
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-116176
Abstract: Introduction: Emicizumab, a bispecific antibody to factors IXa/X, was approved by the Food and Drug Administration in 2017 for prophylactic treatment of persons with hemophilia A (PwHA) with inhibitors. Compared with other treatments for PwHA,… read more here.
Keywords: pwha inhibitors; treatment; management; emicizumab ... See more keywords